Bristol Historical Cash Flow
| BMY Stock | USD 58.90 0.31 0.52% |
Analysis of Bristol Myers cash flow over time is an excellent tool to project Bristol Myers Squibb future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 14.6 B or Change In Working Capital of 850.5 M as it is a great indicator of Bristol Myers ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bristol Myers Squibb latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bristol Myers Squibb is a good buy for the upcoming year.
Bristol |
About Bristol Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bristol balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bristol's non-liquid assets can be easily converted into cash.
Bristol Myers Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Bristol Myers Squibb to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bristol Myers operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Bristol Myers' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Bristol Myers reported Sale Purchase Of Stock of (5.16 Billion) in 2024. Free Cash Flow is likely to rise to about 14.6 B in 2025, despite the fact that Change To Inventory is likely to grow to (461.7 M).
Bristol Myers cash flow statement Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (7.3B) | (1.5B) | (6.3B) | (8.0B) | (5.2B) | 0.0 | |
| Change To Inventory | 2.7B | 13M | (69M) | (751M) | (486M) | (461.7M) | |
| Change In Cash | 2.2B | (657M) | (5.0B) | 2.2B | (1.2B) | (1.1B) | |
| Free Cash Flow | 13.3B | 15.2B | 11.9B | 12.7B | 13.9B | 14.6B | |
| Change In Working Capital | 983M | (1.3B) | (2.2B) | (1.9B) | 810M | 850.5M | |
| Begin Period Cash Flow | 12.8B | 15.0B | 14.3B | 9.3B | 11.5B | 12.1B | |
| Other Cashflows From Financing Activities | 542M | 641M | 7.1B | 27M | (106M) | (100.7M) | |
| Depreciation | 10.4B | 10.7B | 10.3B | 9.8B | 9.6B | 10.1B | |
| Other Non Cash Items | 9.9B | 570M | 955M | 744M | 15.3B | 16.1B | |
| Dividends Paid | 4.1B | 4.4B | 4.6B | (4.7B) | (4.9B) | (4.6B) | |
| Capital Expenditures | 753M | 973M | 1.1B | 1.2B | 1.2B | 852.4M | |
| Total Cash From Operating Activities | 14.1B | 16.2B | 13.1B | 13.9B | 15.2B | 15.9B | |
| Net Income | (9.0B) | 7.0B | 6.3B | 8.0B | (8.9B) | (8.5B) | |
| Total Cash From Financing Activities | (1.2B) | (16.2B) | (17.0B) | (9.4B) | 5.1B | 5.4B | |
| End Period Cash Flow | 15.0B | 14.3B | 9.3B | 11.5B | 10.3B | 5.3B | |
| Stock Based Compensation | 779M | 583M | 457M | 518M | 507M | 275.0M | |
| Total Cashflows From Investing Activities | (10.9B) | (538M) | (1.1B) | (2.3B) | (2.1B) | (2.2B) | |
| Change To Account Receivables | (3.0B) | (2.1B) | (663M) | (995M) | 264M | 277.2M | |
| Other Cashflows From Investing Activities | (12.2B) | (862M) | (3.0B) | 1.1B | 989.1M | 1.0B | |
| Change To Liabilities | 1.1B | (2.1B) | 45M | (887M) | (798.3M) | (758.4M) | |
| Change To Netincome | (62M) | (197M) | (748M) | (1.1B) | (970.2M) | (921.7M) | |
| Investments | 2.1B | 1.3B | 3.0B | 264M | (21.4B) | (20.3B) | |
| Change Receivables | 752M | (646M) | (1.1B) | (663M) | (596.7M) | (566.9M) | |
| Net Borrowings | 17.7B | 3.9B | (6.2B) | (5.3B) | (6.1B) | (5.8B) | |
| Cash And Cash Equivalents Changes | 5.9B | 2.0B | (555M) | (5.0B) | (5.7B) | (5.4B) | |
| Cash Flows Other Operating | 572M | 13.0B | 251M | (858M) | (986.7M) | (937.4M) | |
| Change To Operating Activities | 702M | 1.1B | 606M | (183M) | (210.5M) | (199.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.